Synlogic stock.

Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

A. Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat ...

Synlogic beat estimated earnings by 3.75%, reporting an EPS of $-2.57 versus an estimate of $-2.67. Revenue was down $285 thousand from the same period last year. Past Earnings PerformanceFourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...

CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update. November 30, 2022.The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.

So should Synlogic (NASDAQ:SYBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...

The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

On November 7, 2023, Synlogic, an innovative biotechnology company, proudly announced that it has reached a significant milestone in its collaboration with Roche. This achievement marks the successful completion of the third pre-specified research milestone, resulting in a milestone payment of $2.5 million. The collaboration between Synlogic ...The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price.Synlogic Announces Reverse Stock Split. September 27, 2023. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), ...September 27, 2023 at 12:31 pm EDT. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split …Following the reverse split, shares are trading at about $3.95 this morning. SYBX stock is down 5.6% as of Thursday morning, with some 2,000 shares changing hands. For the record, the company’s ...When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...Nov 30, 2022 · Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. So should Synlogic (NASDAQ:SYBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...

Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

So should Synlogic (NASDAQ:SYBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Nov 27, 2023 · What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00. Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug ...Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...

View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.

The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Stocks whose Next Earnings Date falls within the next 7 days are highlighted in red. Annual Dividend & Yield: The indicated annual dividend rate and yield, calculated from the latest dividend. The dividend rate is ...What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Aoife Brennan, Synlogic CEO. Synlogic “We have been working with Ginkgo for over two years now,” said Aoife Brennan, Synlogic CEO. “We initially started with a pilot project that went so ...CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low …What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ...A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price target for 6.00 expecting SYBX to rise to within 12 ...See Synlogic, Inc. (SYBX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 10, 2022 . Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Add to watchlist. 1.9600 -0.1400 (-6.67%) At close: 03:55PM EST. 1d.6.12%. $26.33M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Synlogic, Inc. (SYBX) is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases. The stock price, news, quote and history of SYBX are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield and more.Instagram:https://instagram. defense+companies+stock+market+newsbest stocks 2023cntb stockj.p. morgan personal advisors If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Synlogic’s pipeline is fueled by its Synthetic Biotic platform, which applies precision engineering to well-characterized probiotics. This creates GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for diseases such as PKU and HCU, both inborn errors of metabolism, as well as others in … walmart dividenttos forex The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter. meta balance sheet Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ... CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock …Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ...